ATOMICC trial: a randomized, open-label, phase II trial of anti-PD1, dostarlimab, as maintenance therapy for patients with high-risk locally advanced cervical cancer after chemoradiation
- Garcia-Duran, C.
- Grau, F.
- Villacampa, G.
- Oaknin, A.
ISSN: 1525-1438, 1048-891X
Datum der Publikation: 2022
Ausgabe: 32
Nummer: 9
Seiten: 1196-1200
Art: Artikel